The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

Completed · Phase 3

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.

Key facts

Study ID

NCT01213017

Run by

Oklahoma Medical Research Foundation

People needed

20

Starts

2010-09-01

Expected to finish

2012-04-01

Last updated by the study team

2017-12-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• moderate to severe RA (DAS > 4.4)
• at least two swollen and tender joints in one of the hand/ wrist
• patients must have failed at least one non-biologic or biologic DMARDs
• currently receiving MTX therapy

You may not qualify if…

• concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment

Where it is running

• Arthritis and Rheumatic Disease Specialties — Aventura, Florida, United States
• Oklahoma Medical Research Foundation — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.